Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer With Germline BRCA1/2 Mutations
NCT04548752Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2021
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in pancreatic adenocarcinoma (PDAC), sponsored by National Cancer Institute. Started Feb 2021; status: active, not recruiting.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04548752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548752.